World wide shipping
Medicines from all over the world
We will help you find any drug in 24 hours
Prices for medicines are presented for informational purposes only

TECENTRIQ/ТЕЦЕНТРІК 1200 MG 20 ML 1 FLK. (atezolizumab,атезолізумаб) Ф.Хоффманн-Ля Рош, Швейцарія

In Stock
0 $
1 400 $
+
Description

Indication

Urothelial Carcinoma:

Treatment for adult patients with locally advanced or metastatic urothelial carcinoma:

  • Ineligible for cisplatin-containing chemotherapy and whose tumor expresses PD-L1 (PD-L1-stained immune cells infiltrating the tumor covering ≥ 5% of the tumor area), or
  • Ineligible for any platinum-containing chemotherapy regardless of the level of PD-L1 expression by the tumor.

Non-Small Cell Lung Cancer (NSCLC):

First-line treatment in monotherapy for adult patients with metastatic non-small cell lung cancer (NSCLC) showing high PD-L1 expression (PD-L1-stained tumor cells ≥ 50% or PD-L1-stained immune cells infiltrating the tumor covering ≥ 10% of the tumor area) and lacking EGFR or ALK genomic tumor aberrations.

First-line treatment in combination with bevacizumab, paclitaxel, and carboplatin for adult patients with metastatic non-squamous NSCLC without EGFR or ALK genomic tumor aberrations.

First-line treatment in combination with protein-bound paclitaxel and carboplatin for adult patients with metastatic non-squamous NSCLC without EGFR or ALK genomic tumor aberrations.

Treatment for adult patients with metastatic NSCLC observing disease progression during or after chemotherapy that includes platinum agents. In patients with EGFR or ALK genomic tumor aberrations, disease progression on therapy approved for NSCLC harboring such aberrations should be observed before receiving Tecentriq®.

Small Cell Lung Cancer (SCLC):

First-line treatment in combination with carboplatin and etoposide for adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Hepatocellular Carcinoma:

Treatment in combination with bevacizumab for patients with unresectable or metastatic hepatocellular carcinoma who haven't received prior systemic therapy.

 

Features
  • Commercial name:
    Тецентрик
  • Сhemical name:
    атезолізумаб
  • Dosage:
    1200 мг
  • Quantity:
    one
  • Release form:
    Bottle
  • Производитель:
    Roche, Германия
Reviews
Андрей
Благодарю за оперативную реакцию на мой заказ! Особенно хочу отметить две вещи: первое - цена на порядок ниже, чем средняя по стране; второе - доставка препарата в специальном контейнере, оперативно, температура хранения выдержана. Спасибо
Write Review
Name*
Email
Write a Review*